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Pharmacology and application
Colistin is a cationic polypeptide antibiotic, a mem-
ber of the polymyxin family of molecules. It was iso-
lated for the first time in 1949 as a product of Paeni-
bacillus polymyxa (formerly Bacillus polymyxa), which 
is an industrially significant facultative anaerobic, 
non-pathogenic, and endospore-forming bacillus. The 
polymyxin molecule consists of a peptide and a fatty 
acid residue. Based on the amino acid sequence of the 
peptide, five polymyxin (A – E) variants can be distin-
guished but only two variants are used in medicine, 
B and E (colistin). The antibacterial effect of colistin 
is concentration-dependent (Li 2005; Das et al. 2017). 
Colistin is only active against Gram-negative bacteria 
(GNB), such as the aerobic Enterobacterales ord. nov. 
(except Proteus spp., Providencia spp., Serratia spp., 
Edwardsiella spp., Morganella spp., and Hafnia spp.), 
non-fermenting rods of Pseudomonas, Acinetobacter 
and Burkholderia, and anaerobic bacteria, e.g. Fusobac-
terium and Bacteroides (except Bacteroides fragilis) (Li 
et al. 2005). Its antibacterial mechanism is based on the 
electrostatic interaction between colistin amino groups 
and lipid A subunits of lipopolysaccharide (LPS). Colis-
tin displaces Mg2+ and Ca2+ ions from LPS, leading to 
disturbances in the outer membrane structure of the 
cell. This leads to increased permeability of the cell 
membrane and, consequently, to cell death (Schindler 
and Osborn 1979).
As polymyxins are poorly absorbed from the diges-
tive tract, orally administered polymyxins are only active 
on bacteria in the gastrointestinal system. Poly myxins 
do not diffuse well into tissues and do not penetrate the 
cerebrospinal fluid or the pleural and peritoneal cavity. 
Colistin has numerous side effects, including nephro-
toxicity and neurotoxicity; therefore, it cannot be used 
in patients with renal failure (Kostowski and Herman 
2010). The levels of nephrotoxicity and neuroto- 
xicity were the reason for its discontinued use in human 
medicine after 1970 (Tullu and Dhariwal 2013).
In medicine, two physical forms of colistin are avail-
able, colistin sulphate (CS) for oral and topical use, and 
colistin methanesulphonate (CMS) for parenteral use 
(Kwa et al. 2005; Li et al. 2005). Nephrotoxicity and 
neurotoxicity are dose-dependent (Ordooei Javan et al. 
2015). Risk factors for nephrotoxicity include colistin 
plasma levels > 2.5–3 g/l, concomitant administration 
of other nephrotoxic drugs (such as anti-inflammatory 
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drugs, vancomycin and aminoglycosides), the advanced 
age of patient, and severity of the disease (rates of 
nephrotoxicity 14–53%) (Kwon et al. 2010; Pogue et al. 
2011). Neurotoxicity is reversible and manifests itself, 
among others, in the form of peripheral and facial 
paresthesia, dizziness/vertigo, weakness, visual dis-
turbances, and ataxia (4–6% of patients) (Koch-Weser 
et al. 1970; Spapen et al. 2011). Colistin methanesulpho-
nate has no antimicrobial activity and acts as a colistin 
pro-drug that does not bind to plasma proteins. After 
parenteral administration, approximately 20% of CMS 
is hydrolyzed to colistin. This is an important feature 
in reducing toxicity, especially nephrotoxicity (Falagas 
et al. 2005). When given intravenously, a large por-
tion of CMS is eliminated mainly through the kidneys 
by glomerular filtration and tubular secretion, which 
allows the use of CMS in urinary tract infections (Kos-
towski and Herman 2010). The intravenous (IV) form 
of the drug may also be administered by inhalation (Li 
et al. 2005). Inhaled colistin is used for treating pneu-
monia and ventilator-associated pneumonia (VAP) 
caused by multidrug-resistant (MDR) Gram-negative 
microorganisms, while it is also used prophylactically 
in patients with cystic fibrosis. Colistin also causes the 
release of histamine and serotonin by monocytes, which 
can lead to acute respiratory failure; therefore, care is 
needed when administering this drug in the form of an 
aerosol (Dzierżanowska 2018).
In the last 20 years, the emergence of MDR Gram-
negative bacilli has led to polymyxins B and E  being 
used once again, as a “salvage” therapy in the patients 
with CRE (carbapenems-resistant Enterobacteriaceae) 
infections for which we do not have the better treat-
ment options (Li et al. 2006; Nation and Li 2009; Lim 
et al. 2010). Orally and topically administered colistin 
sulphate and parenteral colistin methanesulphonate 
sodium are designed for the treatment of life-threaten-
ing human infections caused by Gram-negative rods. 
Colistin has been approved by the American Thoracic 
Society and Infectious Diseases Society of America, 
who have provided guidelines for the treatment of 
VAP caused by MDR Gram-negative rods (American 
Thoracic Society and Infectious Diseases Society of 
America 2005). The parenteral form of colistin has also 
been evaluated for the treatment of other serious infec-
tions caused by MDR P. aeruginosa, A. baumannii, and 
Enterobacteriaceae, such as sepsis, abdominal infections, 
bone and joint infections, urinary tract infections, and 
meningitis (Falagas et al. 2005; Walkty et al. 2009; Batirel 
et al. 2014). Recent studies have demonstrated accept-
able effectiveness and considerably less toxicity than had 
been reported on polymyxins in older studies (Ordooei 
Javan et al. 2015). However, randomized controlled 
trials are urgently needed to further clarify the issues 
surrounding the efficacy and safety of polymyxins.
Colistin resistance mechanisms
Bacteria acquire resistance to colistin as a result 
of mutations and adaptation mechanisms. Different 
molecular mechanisms are associated with colistin 
resistance in Gram-negative bacteria; there are, among 
others, changes in the two-component systems: pmrA/
pmrB (Escherichia coli, Klebsiella pneumoniae, Salmo-
nella spp., Acinetobacter baumannii, and Pseudomonas 
aeruginosa), phoP/phoQ (K. pneumoniae, Salmonella 
spp.), parR/parS (P. aeruginosa), colR/colS (P. aerugi-
nosa), and cprR/cprS (Campylobacter jejuni) (Olaitan 
et al. 2014b). Mechanisms of resistance differ among 
Gram-negative bacterial species. The most impor-
tant chromosomal mechanism of colistin resistance 
in K. pneumoniae is an alteration of the mgrB gene, 
which encodes a negative regulator of phoP/phoQ sys-
tem (Jayol et al. 2015). Colistin resistance is mainly 
achieved by modification of LPS, which is the main 
target of colistin in the bacterial cell. Mutations that 
lead to the addition of cationic groups to lipid A weaken 
the binding of polymyxins (Olaitan et al. 2014b; Baron 
et al. 2016). In the case of A. baumannii, similar changes 
in the lpxA, lpxC and lpxD genes as described above, 
cause inhibition of lipid A biosynthesis and thus loss 
of the polymyxin target in the bacteria (Moffatt et al. 
2010). There is the hypothesis that colistin resistance 
of clinical isolates results from a combination of porin 
mutations and overexpression of efflux pump systems 
(Olaitan et al. 2014b).
Bacterial colistin resistance may be coded on trans-
posable genetic elements (mostly plasmids with the mcr 
genes). Thus far, nine variants of the mcr genes, mcr-1 
– mcr-9, have been identified in various Enterobacte-
rales and Moraxella species. The first plasmid-mediated 
colistin resistance was detected in an E. coli strain col-
lected from food animals in China in 2015 (Liu et al. 
2016). Since then, the plasmid-mediated colistin resist-
ance in Enterobacterales has been reported worldwide, 
including human infections, also from Poland (Izdebski 
et al. 2016). The mcr-1 gene modifies LPS by encoding 
phosphoethanolamine transferase (pEtN transferase), 
which mediates the addition of pEtN to lipid A (Baron 
et al. 2016). Generally, E. coli strains with the mcr-1 
gene are characterized by the low-level colistin resist-
ance with a minimum inhibitory concentration (MIC) 
in the range of 2–8 mg/l. Zhang et al. (2019) have shown 
that the expression of the mcr-1 gene in E. coli led to 
a higher mutation rate in the chromosomal polymyxin 
resistance cascade genes and produced higher MIC 
values (≥ 64 mg/l).
The mcr-2 gene was first identified by Xavier and col-
leagues in E. coli strains isolated from calves and pigs in 
Belgium; MCR-1 and MCR-2 proteins showed 80.65% 
identity (Xavier et al. 2016). In 2017, a third mobile 
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colistin resistance gene, mcr-3, was described in E. coli 
by Yin et al. (2017). The amino acid sequence of the 
mcr-3 gene product, MCR-3, showed 32.5 and 31.7% 
amino acid identity to MCR-1 and MCR-2, respectively 
(Yin et al. 2017). Also, Carrattoli et al. (2017) in 2017 
detected a new plasmid-mediated colistin gene, mcr-4, 
in Salmonella on a small, not self-conjugative plasmid. 
For the first time, Borowiak et al. (2017) described 
a  novel transposon-associated phosphoethanolamine 
transferase gene, mcr-5, which conferred colistin resist-
ance in d-tartrate-fermenting Salmonella enterica subsp. 
enterica serovar Paratyphi B. In 2018, further variants, 
the mcr-6 – mcr-8 genes, were described (AbuOun et al. 
2017; 2018; Wang et al. 2018; Yang et al. 2018).
Recently, Carroll et al. (2019) have described the 
mcr-9 gene, a novel mcr homologue detected in MDR 
colistin-susceptible Salmonella enterica serovar Typhi-
murium strain isolated from a patient in the Washing-
ton State in 2010. This strain was phenotypically sensi-
tive to colistin with a MIC value of 2 mg/l, according 
to the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) recommendations. The mcr-9 
gene was cloned into colistin-sensitive E. coli and the 
expression-conferred E. coli NEB5α strain with resist-
ance to 1, 2 and 2.5 mg/l colistin. Pairwise compari-
son of the predicted protein structures of all nine mcr 
homologues (mcr-1 to mcr-9) revealed that the mcr-3, 
mcr-4, mcr-7, and mcr-9 genes share a high degree of 
similarity at the structural level (Carroll et al. 2019).
Colistin uses in human medicine
Colistin is used for treating infections with carba- 
penem-resistant Enterobacteriaceae (CRE) that belong 
to multi-resistant isolates and have already been 
reported worldwide (Grundmann et al. 2010). The seri-
ousness of the problem is underlined by high (> 30%) 
mortality of hospitalized patients infected with car-
bapenem-resistant strains (Capone et al. 2013; Ghafur 
et al. 2014; Guducuoglu et al. 2018; Zhang et al. 2018). 
Such infections are difficult to treat and with limited 
therapeutic options (Parisi et al. 2015; Baraniak et al. 
2016). Tumbarello et al. (2012) analyzed the course of 
K. pneumoniae KPC-positive infection in the patients; 
combination therapy with tigecycline, colistin, and 
meropenem was associated with a lower risk of mor-
tality (12.5%). The authors also indicate that incor- 
rect empirical therapy is a  significant factor in the 
mortality rate of the patients infected with carbape-
nem-resistant K. pneumoniae (Tumbarello et al. 2012; 
Tumbarello et al. 2015).
Moreover, the development of outbreaks by colis-
tin-resistant Gram-negative bacilli producing carbape-
nemases is a great problem (Antoniadou et al. 2007; 
Marchaim et al. 2011; Monaco et al. 2014; Olaitan et al. 
2014a; Parisi et al. 2015; Jayol et al. 2016; Gundogdu 
et al. 2018). In 2013, the colistin resistance rate has risen 
to an average of over 30% of CRE isolates, including 
Italy, Spain, and Greece, and constituted accordingly 
43, 31, and 20.8%, respectively (ECDC 2014; Monaco 
et al. 2014; Pena et al. 2014; Meletis et al. 2015). The 
increased mortality is also related to infections with 
colistin-resistant strains (Capone et al. 2013). Colistin 
resistance makes the choice of antimicrobial agents 
difficult, and the use of therapeutic options for colis-
tin-resistant MDR isolates depends on the sensitivity 
phenotype of the isolates, the infection type and site, 
antimicrobial PK/PD properties, and potential side 
effects (Petrosillo et al. 2019).
Due to the increasing role of colistin in the treat-
ment of human infections with MDR bacteria, the 
resistance to this antibiotic should be carefully moni-
tored. The use of colistin in human medicine is assumed 
to be a cause for the occurrence of colistin resistance in 
Enterobacterales, particularly in K. pneumoniae (Sandri 
et al. 2013; Vicari et al. 2013).
Ceftazidime/avibactam, as a combination of β-lac-
tam and β-lactamases inhibitor, plays an important role 
in the treatment of MDR K. pneumoniae infections, 
including colistin-resistant isolates producing KPC 
(Jayol et al. 2018a). It is registered for the treatment 
of abdominal infections, urinary tract infections and 
nosocomial pneumonia (Zhanel et al. 2013). Avibactam 
inhibits class A, C, and D β-lactamases, including KPC 
and OXA-48 carbapenemases (Shields et al. 2015; Pogue 
et al. 2019), but does not inhibit metallo-β-lactamases 
(Ambler class B) due to the absence of the active-site 
serine residue in these enzymes (Davido et al. 2017). 
The combination of ceftazidime/avibactam with aztre-
onam showed activity against K. pneumoniae strains, 
regardless of the type of carbapenemase produced 
(Davido et al. 2017; Jayol et al. 2018a). Ceftazidime/ 
avibactam therapy is less nephrotoxic compared to 
amino glycosides or colistin (Zhanel et al. 2013). How-
ever, it has been reported that K. pneumoniae acquired 
resistance to ceftazidime with avibactam during treat-
ment (Shields et al. 2017; Gaibani et al. 2018).
The combination of meropenem with vaborbac- 
tam is the new antimicrobial agent active against 
KPC-positive K. pneumoniae (Pfaller et al. 2018; Pogue 
et al. 2019), and it is registered for the treatment of 
respiratory pneumonia and bacteraemia (U.S. Natio- 
nal Library from Medicine 2019). Vaborbactam does 
not inhibit class D or class B carbapenemases and 
due to the risk of developing resistance, meropenem/
vaborbactam should be reserved for the treatment of 
infections caused by MDR strains, including colistin-
resistant K. pneumoniae KPC-positive (Lomovskaya 
et al. 2017).
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Methods for susceptibility testing
It is highly important to develop phenotypic tests 
capable of detecting the colistin resistance in Gram-
negative rods. Until recently, there was no consensus 
as to the methodology for colistin susceptibility testing. 
The disc diffusion method and gradient tests proved 
to be unreliable due to the poor diffusion of colistin 
in agar (Galani et al. 2008; Behera et al. 2010; Dafopou-
polu et al. 2015; Chew et al. 2017; Vasoo 2017; Giske 
and Kahlameter 2018). Therefore, disk diffusion and 
gradient diffusion are not valid techniques for the 
determination of susceptibility to polymyxins.
In 2016, both EUCAST and the Clinical and Labo-
ratory Standards Institute (CLSI) recommended the 
International Standard Organization (ISO) 20776 
standard broth dilution method for testing of the MIC 
values of colistin (CLSI 2016; EUCAST 2016). How-
ever, the reference broth microdilution method is dif-
ficult to apply in routine microbiological diagnostics. 
The EUCAST does not recommend the use of auto-
mated systems to determine the phenotype of bac- 
terial sensitivity such as Vitek 2, (bioMerieux, France), 
BD Phoenix (Becton Dickinson, USA), as well as Walk-
Away (Beckman Coulter, USA) for the analysis of the 
sensitivity of Gram-negative bacilli to colistin. This is 
because these systems have fairly limited accuracy in 
determining colistin MIC, particularly in the range 
of 2–4 mg/l when compared to the reference method 
(Nordmann et al. 2016b; Bosacka et al. 2018; Matuschek 
et al. 2018b; Lellouche et al. 2019).
The literature data indicate the usefulness of several 
commercially available systems that are based on the 
broth microdilution method, such as the MIC-Strip 
Colistin (Merlin,Germany), Microlatest MIC Colistin 
(Erba Lachema, Czech Republic), Sensitest Colistin 
(Liofilchem, Italy), and MIC COL (Diagnostics, Slo-
vakia) for the evaluation of the sensitivity of Entero-
bacterales and non-fermenting rods to colistin (Nord-
mann et al. 2016b; Matuschek et al. 2018a; Bosacka 
et al. 2018; Lellouche et al. 2019). Members of colistin-
resistant bacilli are usually correctly categorized as 
resistant using the above-mentioned methods (Chew 
et al. 2017; Poirel et al. 2017). An increasing number 
of recent reports point to the heterogeneity of strains 
detected via microdilution in broth (Chew et al. 2017).
Methods for the detection of colistin resistance
The innovatory technique for the identification of 
colistin resistance is the Rapid Polymyxin NP (Nord-
mann/Poirel) test. It was developed by the Nordmann’s 
group for the colistin susceptibility testing in Entero-
bacterales (Nordmann et al. 2016b). Currently, the 
rese archers are underway to use this test for the detec-
tion of colistin resistance in non-fermenting bacilli. 
The Rapid Polymyxin NP test detects fermentation of 
glucose associated with bacterial growth in the pres-
ence of a defined concentration of polymyxin E or B; 
the presence of acid metabolites is evidenced by the 
change in the pH and the indicator (red phenol) color 
from orange to yellow. The sensitivity and specificity 
of the test are highly comparable to the reference broth 
microdilution method (99.3 and 95.4%, respectively). 
This test is easy to perform and provides a result in less 
than 2 hours (Nordmann et al. 2016b).
Chromogenic media are commonly used for screen-
ing; they allow the growth of sought bacteria as prop-
erly colored colonies. The first agar medium for detect-
ing colistin-resistant Gram-negative rods from bacterial 
cultures and rectal swab samples was the SuperPoly-
myxin screening medium (Nordmann et al. 2016a); the 
commercial version of this medium is SuperPolymyxin 
medium (ELITechGroup, Puteaux, France) for detect-
ing colistin-resistant Enterobacterales strains, including 
these with the low MIC values (mg/l) that harbor the 
mcr-1 gene (Jayol et al. 2018). It is composed of eosin 
methylene blue (EMB) agar and includes colistin, dap-
tomycin, and amphotericin B (3.5, 10, and 5 µg/ml, 
respectively). The other medium, CHROMagar COL-
APSE medium for the detection of colistin-resistant 
strains was compared to the SuperPolymyxin medium 
(Abdul Momin et al. 2017); this medium differentiates 
colistin-resistant Enterobacterales strains from non-fer-
menting rods. Bardet et al. (2017) described the LBJMR 
medium, a new polyvalent culture medium for the iso-
lation and selection of colistin-resistant bacteria and 
vancomycin-resistant bacteria. This medium was devel-
oped by the addition of colistin sulphate salt (4 µg/ml), 
vancomycin (50 µg/ml), and a substrate for fermenta-
tion (7.5 g/l of glucose) to a Purple Agar Base (31 g/l). 
In early 2018, a new chromogenic medium, CHRO-
MID Colistin R agar (COLR; bioMérieux, France) came 
into the market and allowed the screening of colistin-
resistant Enterobacteriaceae in clinical samples, such as 
stools and rectal swabs. The COLR is a manual qualita-
tive diagnostic test, which allows colistin-resistant iso-
lates to be distinguished from those that are susceptible. 
Colistin-resistant strains forming colored colonies on 
chromogenic media and their color depends on the 
species. By contrast, colistin-susceptible isolates do not 
grow on the COLR plate (García-Fernández et al. 2019).
The chromogenic method is based on the dilution 
in agar, although EUCAST does not recommend this 
procedure for the determination of bacterial suscep-
tibility to colistin, as the threshold of the detectability 
increases with the growth of the bacterial inoculum 
(Matuschek et al. 2018b). However, Turlej-Rogacka 
et al. (2018) reported that when compared to broth 
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dilution methods, the method of the dilution in agar 
yields more accurate results in the evaluation of the 
colistin MIC values (Turlej-Rogacka et al. 2018). Behera 
and colleagues (2010) confirmed the high correlation 
of results between the reference method and the agar 
dilution method (Behera et al. 2010; Dafopouolu et al. 
2015). The greatest challenge in colistin handling is its 
binding to plastic (Humphries 2015; Matuschek et al. 
2018b). According to the above-mentioned authors, 
the agar dilution method significantly reduces the 
phenomenon of colistin-plastic binding, and the MICs 
results obtained with this method are characterized by 
a high accuracy (Behera et al. 2010; Humphries 2015; 
Matuschek et al. 2018).
The COLR medium uses the borderline colistin 
concentrations that allow qualification of the strains 
studied as susceptible or resistant. This chromogenic 
medium is a  qualitative method of Enterobacterales 
detection and does not allow the determination of the 
colistin MIC values against the bacterial strains ana-
lyzed. As such, it should only be regarded as a screen-
ing test. On the other hand, in treating the infections 
caused by colistin-resistant bacteria, the clinical inter-
pretation is significant. This entails the categorization 
of colistin resistance rather than the determination 
of the specific MIC value since maximum dosages of 
the medication are prescribed independently of pre-
cise susceptibility levels. However, the MIC values are 
important in monitoring the increase in the resistance 
to colistin observed in the intestinal bacteria.
Other new-generation methods have been devel-
oped recently to detect colistin-resistant strains: the 
loop-mediated isothermal amplification (LAMP) for 
nucleic acid detection (Zou et al. 2017), and a micro-
array CT103XL (Bernasconi et al. 2017). Zou et al. 
(2017) showed that the LAMP test is ten times more 
sensitive than the conventional PCR and confirmed 
its usefulness for the detection of the mcr-1 gene in 
Enterobacterales strains from stool samples. Similarly, 
Bernascini et al. (2017) demonstrated the usefulness of 
the new CT103XL microarray for the rapid characteri-
zation of multidrug-resistant Gram-negative bacteria 
through simultaneously identifying the mcr-1, mcr-2, 
and clinically important bla genes.
Colistin in veterinary medicine and agriculture
Colistin sulphate has also been widely and heavily 
used for decades in veterinary medicine for the treat-
ment of intestinal infections in pigs, poultry, and cattle, 
which were caused by Enterobacterales strains, mainly 
E. coli and Salmonella spp. (Liu et al. 2016). In these 
situations, colistin is chiefly used in an oral form, and its 
usage varies widely among different countries. In Spain, 
it is used during gestation and lactation, the post-wean-
ing period, and for metaphylactic intestinal disease con-
trol (Casal et al. 2007). During the post-weaning period, 
it is used in 50% and 35% of pig farms in France and 
Austria, respectively (Kempf et al. 2013; Trauffler et al. 
2014). In Sweden, colistin was the most frequently used 
antibiotic in 18% of weaned piglet herds (Sjölund et al. 
2015). A German study on antimicrobial use in pigs 
has revealed that polypeptides accounted for 4.2% of 
the total use per kg but regarding treatment units, they 
were among the three most frequently used antimicro-
bial classes (van Rennings et al. 2015). A Netherland 
study has shown that colistin, as one of the most used 
antimicrobials next to tetracyclines, trimethoprim/sul-
fonamides, macrolides, and lincosamides was available 
on the prescription and deliveries for pigs, veal calves, 
and broilers in the country (Bos et al. 2013).
In Asian countries, the use of antibiotics, particu-
larly colistin, in animal husbandry also takes place on 
a large scale. China is one of the world’s largest users of 
colistin in agriculture; over 11 thousand tons of colistin 
is being used (QYResearch Medical Research Centre 
2015). Considering this upward trend, the consump-
tion of colistin in Chinese agriculture is estimated to 
reach more than 16 thousand tons in 2021 (QYResearch 
Medical Research Centre 2015). China remains the 
largest user of colistin in agriculture worldwide. In the 
Red River Delta region of Vietnam, colistin was also 
used as a feed additive for growth promotion in pig pro-
duction (Kim et al. 2013). This was a cause of concern 
because colistin is an unapproved antibiotic for growth 
promotion in Vietnam (MARD 2006; 2009). These facts 
illustrate the sheer scale of antibiotic consumption in 
animal and poultry husbandry.
Alarming data on the use of antibiotics in veterinary 
medicine, in particular colistin, has led to efforts to limit 
their use. The different monitoring systems for the use 
of antibiotics in animals and the surveillance of resist-
ance to antibiotics were established in European coun-
tries (BTK 2015; Borck Høg et al. 2017; SDa Autoriteit 
Diergenesmiddelen 2018; SWEDRES/SVARM 2018; 
MARAN 2019). In 2015, Nunan and Young (2015) 
reported that antibiotics, particularly colistin, should 
not be routinely used as prophylactics in animal farms 
in the United Kingdom (UK). The authors added that 
colistin accounted for only 0.2% of all antibiotics that 
were used in breeding in the UK and was only used by 
veterinarians to treat sick animals (EMA/CVMP 2010; 
Nunan and Young 2015; Catry et al. 2015).
In a national report on antibiotics consumption in 
the Australian pig industry, Jordan et al. (2009) found 
that colistin was not used during the study period in 
the production of pigs.
Until recently, there were no recommendations 
on the need of conducting the screening tests to find 
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the carriage of colistin-resistant bacteria, but under 
a ‘One Health’ perspective, it is necessary to monitor 
the colistin resistance among Gram-negative bacteria 
in veterinary and human medicine. Currently, at least 
in the veterinarian sector in Germany, screening for 
colistin resistance is recommended and carried out rou-
tinely, and efforts are being made to implement colistin 
screening also for human isolates. It, therefore, seems 
justified to develop a chromogenic agar medium for 
detecting colistin-resistant rods directly from clinical 
material other than stools and rectal swabs, e.g. samples 
from the lower respiratory tract or urine samples.
Colistin-resistant strains in plant food
and the environment
There are progressively more and more reports on 
the culture of the colistin-resistant Enterobacterales 
strains from vegetables and fruits samples (Liu et al. 
2014; Jones-Dias et al. 2016; Luo et al. 2017). A study 
by Zhon et al. (2017) showed that water, where live 
bacteria may have come from the excrements, can be 
the source of plant contamination with Gram-negative 
bacilli (Zhon et al. 2017). Jung et al. (2014) analyzed the 
relationship between the plant food production chain 
and the incidence of foodborne disease outbreaks, and 
the consumption of contaminated raw vegetables has 
been linked with these outbreaks (Jung et al. 2014). Liu 
et al. (2014) studied the samples of vegetables (carrots, 
pak choi, green peppers, and leaf lettuce) from super-
markets or farmers’ markets in nine provinces of China; 
about 4% of the vegetable samples (3.6%) carried one 
or more the mcr-positive isolates (E. coli and Enterobac-
ter cloacae); the dissemination of the mcr-1 gene was 
mediated by plasmids. All isolates were MDR; however, 
they were susceptible to meropenem and tigecycline 
(Liu et al. 2014). Jones-Dias et al. (2016) showed the 
presence of the mcr-1 gene in lettuce samples in Portu-
gal (Jones-Dias et al. 2016).
Zurfuh et al. (2016) reported the presence of the 
plasmid-borne mcr-1 colistin resistance gene in the 
extended-spectrum β-lactamase (ESBL) producing 
E. coli strains from rivers and lakes in Switzerland, and 
the ready-to-eat imported vegetables from Asian coun-
tries (Zurfuh et al. 2016). The E. coli strains with the 
mcr-1 genes belonged to different multilocus sequence 
types (MLSTs), which harbored different the blaESBL 
genes. This suggests that the mcr-1 gene can be spread 
on different plasmids. Luo et al. (2017) described the 
identification of the mcr-1 gene in E. coli and Raoultella 
ornithinolytica ESBL-producing isolates collected from 
fresh vegetable samples in Guangzhou, China. Raoul-
tella ornithinolytica belongs to a genus closely related 
to Klebsiella and is an environmental microorganism 
associated with community-acquired infections, but the 
number of R. ornithinolytica infections might have been 
underestimated due to its misidentification as a Kleb-
siella spp. (Luo et al. 2017). Li et al. (2017) showed that 
the mcr-1 gene in isolates from Guangzhou was located 
on IncHI2/ST3, IncI2, and IncX4 plasmids in both iso-
lates from animals and humans. The studies cited here 
differ in the number and variety of the vegetables exam-
ined; however, as vegetables are often consumed raw, 
the presence of bacteria carrying the mcr-1 gene may 
pose a threat to public health.
Summary
The resistance of Gram-negative rods to colistin, 
including Enterobacterales, is a serious public health 
problem. The colistin use in animal husbandry and 
agriculture has an impact on the spread of colistin 
resistance (Catry et al. 2015). The mcr genes were found 
in bacteria isolated from various food sources as ani-
mal meat and vegetables as well as the environment 
(including rivers and lakes water), infected patients, 
and asymptomatic human carriers. The detection of the 
antimicrobial resistance genes is critical for the preven-
tion of the spread of bacterial resistance. There are sev-
eral phenotypic and genotypic methods to detect colis-
tin-resistant strains, determine the colistin MIC values 
and identify colistin resistance mechanisms. The easy 
transmission of resistance genes among microorgan-
isms poses a challenge to the therapy of MDR bacterial 
infections, especially caused by carbapenem-resistant 
Enterobacterales. Therefore, resistance to colistin in the 
members of the Enterobacterales should be perceived 
as an important global health problem, requiring multi-
sectoral, further research as well as a proper monitoring 
and surveillance systems.
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